ViiV Healthcare
ViiV Healthcare (/viːv/ VEEV) is a pharmaceutical company specializing in the development of therapies for HIV infection that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi. This ownership structure may change depending upon the achievement of certain milestones.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Apretude | Cabotegravir | 2021-12-20 | 2025-2031 | |
| Cabenuva | Cabotegravir, Rilpivirine | 2021-01-21 | 2025-2031 | |
| Celsentri | Maraviroc | 2007-09-18 | ||
| Combivir | Lamivudine, Zidovudine | 1997-09-26 | 2027-2036 | |
| Dovato | Dolutegravir, Lamivudine | 2019-04-08 | 2025-2031 | |
| Epivir | Lamivudine | 1995-11-17 | 2027-2036 | |
| Epzicom | Abacavir, Lamivudine | 2004-08-02 | 2027-2036 | |
| Juluca | Dolutegravir, Rilpivirine | 2017-11-21 | 2024-2033 | |
| Kivexa | Abacavir, Lamivudine | 2004-12-16 | 2027-2036 |
1
2
3
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use